Vident Investment Advisory’s Emergent Biosolutions EBS Stock Holding History

Vident Investment Advisory’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-40,844	Closed	-$2.06M	–	505
2019 Q1	$2.06M	Buy	+40,844	New	+$2.41M	0.11%	277
2017 Q1	–	Sell	-29,283	Closed	-$962K	–	439
2016 Q4	$962K	Buy	29,283 +1,639	+6%	+$49.1K	0.12%	288
2016 Q3	$872K	Buy	+27,644	New	+$803K	0.12%	302
2015 Q4	–	Sell	-19,869	Closed	-$566K	–	503
2015 Q3	$566K	Buy	+19,869	New	+$655K	0.08%	465

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

SCM

Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

Vident Investment Advisory's EBS Position: Q2 2019 in Review

Vident Investment Advisory sold out of Emergent Biosolutions (EBS) in Q2 2019, closing a stake of 40,844 shares — an estimated $2.06M sold.

Vident Investment Advisory first reported a position in EBS in Q3 2015 and held it in 4 quarters. The position peaked at $2.06M in Q1 2019. 233 funds tracked by Wall St. Rank hold EBS as of Q2 2019.

Vident Investment Advisory reported no remaining Emergent Biosolutions position as of Q2 2019 after selling out during the quarter.
Vident Investment Advisory sold 40,844 Emergent Biosolutions shares in Q2 2019, an estimated $2.06M.
Vident Investment Advisory first reported a position in Emergent Biosolutions in Q3 2015 and held it in 4 quarters.
Vident Investment Advisory's Emergent Biosolutions position peaked at $2.06M in Q1 2019.
233 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2019.

Based on Vident Investment Advisory's 13F filing for Q2 2019, filed 12 Aug 2019.